Arlocabtagene autoleucel vs JNJ-87562761

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: GPRC5D · full Multiple Myeloma pipeline

Arlocabtagene autoleucel

Developed by Bristol-Myers Squibb and partners

Phase 3 in Multiple MyelomaCAR-T cell therapy
Weak signal

NCT04674813 · Phase 1 · completed

Everyone enrolled knowingly received the therapy, with no random assignment and no comparison group, so response and safety data cannot be separated from how this particular group of patients would have fared anyway. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT06615479 (registry estimate)

Reported efficacy

Number of participants with Adverse Events (AEs) (Up to 2 years after CC-95266 infusion); Number of participants with significant laboratory abnormalities (Up to 2 years after CC-95266 infusion); Number of participants with Dose Limiting Toxicities (DLTs) (Up to 2 years after CC-95266 infusion); Maximum Tolerated Dose (MTD) (Up to 2 years after CC-95266 infusion); Recommended Phase 2 Dose (RP2D) (Up to 2 years after CC-95266 infusion): In 79 efficacy-evaluable patients with heavily pretreated relapsed/refractory multiple myeloma (median 5 prior regimens), the overall response rate was 87%, comprising a 53% complete response rate, a 23% very good partial response rate and an 11% partial response rate.

Result source: NCT04674813

JNJ-87562761

Developed by Johnson & Johnson

Phase 1 in Multiple Myelomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2027 · NCT06604715 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointArlocabtagene autoleucelJNJ-87562761
PFS, median—Trial running · NCT06615479—Not reported
OS, median—Trial running · NCT06615479—Not reported
ORR—Trial running · NCT06615479—Not reported
VGPR or better—Trial running · NCT06615479—Not reported
MRD negativity—Trial running · NCT06615479—Not reported

PFS, median

Arlocabtagene autoleucel
—Trial running · NCT06615479
JNJ-87562761
—Not reported

OS, median

Arlocabtagene autoleucel
—Trial running · NCT06615479
JNJ-87562761
—Not reported

ORR

Arlocabtagene autoleucel
—Trial running · NCT06615479
JNJ-87562761
—Not reported

VGPR or better

Arlocabtagene autoleucel
—Trial running · NCT06615479
JNJ-87562761
—Not reported

MRD negativity

Arlocabtagene autoleucel
—Trial running · NCT06615479
JNJ-87562761
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Arlocabtagene autoleucel: no structured comparison results are available for Multiple Myeloma.

JNJ-87562761: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Arlocabtagene autoleucel's landscape · JNJ-87562761's landscape